Bladder Cancer - Results from #720

REVIEW UroToday

Sex Does Not Affect Survival: A Propensity Score-Matched Comparison in a Homogenous Contemporary Radical Cystectomy Cohort. November 28, 2023

Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy. November 28, 2023

Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients. November 27, 2023

Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies. November 27, 2023

Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guérin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box? November 24, 2023

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review. November 24, 2023

Impact of consensus molecular subtypes on survival with and without adjuvant chemotherapy in muscle-invasive urothelial bladder cancer. November 23, 2023

Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications. November 23, 2023

The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer. November 22, 2023

Squamous cell carcinoma of the bladder: Demographics and outcomes associated with surgery and radiotherapy. November 22, 2023

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice. November 21, 2023

Phase II trial of Concurrent Nivolumab and Radiation therapy in Elderly or Chemotherapy ineligible Muscle Invasive Bladder Cancer. November 21, 2023

Clinical and Molecular Features of Nested and Large Nested Urothelial Carcinoma - Expert Commentary November 20, 2023

Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? November 20, 2023

Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis? November 20, 2023

Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer. November 20, 2023

Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. November 17, 2023

Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition. November 17, 2023

Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancer. November 16, 2023

Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI. November 16, 2023

Page 37 of 517